Most Clicked StoriesMore >


Genentech's Lucentis receives FDA approval for diabetic retinopathy

BIO SmartBrief | Apr 18, 2017

The FDA has approved Lucentis 0.3 mg, Genentech's ranibizumab injection, as a monthly treatment for all types of diabetic retinopathy, with or without the presence of diabetic macular edema, the company said. The expanded approval was based on the Diabetic Retinopathy Clinical Research Network's Protocol S study. Medscape (free registration) (04/17) Reuters (04/17)


BMS to develop NASH, fibrotic disease biomarkers with Nordic Bioscience

BIO SmartBrief | Apr 18, 2017

Plant breeder grows 45-foot-high corn stalks

BIO SmartBrief | Apr 18, 2017

FDA OKs Tecentriq as first-line bladder cancer drug

BIO SmartBrief | Apr 19, 2017

Lion Biotechnologies to partner with MD Anderson on TIL cancer drugs

BIO SmartBrief | Apr 20, 2017

Ethanol content in US gasoline reaches new high

BIO SmartBrief | Apr 20, 2017

FDA grants breakthrough status to Novartis' CAR T-cell lymphoma candidate

BIO SmartBrief | Apr 19, 2017

Allergan, Novartis to partner for NASH combo drug study

BIO SmartBrief | Apr 19, 2017

Allergan introduces rosacea cream

BIO SmartBrief | Apr 20, 2017

Biogen, Roche gain licenses to BMS experimental drugs

BIO SmartBrief | Apr 17, 2017


Find BIO SmartBrief Issues by Date:



BIO News More >


Register for BIO's Executive Training courses

BIO SmartBrief | Apr 21, 2017

Register for BIO Talent Connect, BIO's Career Growth Opportunity at BIO 2017

BIO SmartBrief | Apr 21, 2017

Become an advocate for biotechnology

BIO SmartBrief | Apr 20, 2017

Nikon

BIO SmartBrief | Apr 19, 2017

Registration for BIO 2017 World Congress now open

BIO SmartBrief | Apr 19, 2017




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more